VITAL KSK HOLDINGS,INC.
3151・Prime Market・Wholesale Trade
Business
Vital KSK Holdings is a joint holding company established in 2009 through a share transfer involving Vital Net Co., Ltd. (Tohoku/Niigata market area) and KSK Co., Ltd. (Kinki region, spanning two prefectures and four other areas). With pharmaceutical wholesaling as its core business, the company operates a dispensing pharmacy business (pharmacy segment), veterinary pharmaceutical wholesaling (veterinary pharmaceutical wholesaling segment), nursing care rental, 3PL, and consulting services (nursing care rental and other business), and a pharmaceutical business supporting the domestic introduction of drugs approved or unapproved in Europe and the US (unapproved drug introduction support segment). Its main customers are medical institutions such as hospitals, clinics, and dispensing pharmacies, with consolidated group net sales reaching ¥610,497 million (FY2026, ending March 2026).
Business Model
The revenue model is fundamentally based on purchasing pharmaceuticals from manufacturers and wholesaling them to hospitals and pharmacies to earn a trading margin. The gross profit margin is thin, at around 8%, but profitability is maintained through rigorous item-by-item price negotiations based on the distribution improvement guidelines and through contribution profit management. In addition, the company combines dispensing fee income from dispensing pharmacies, wholesale margins on veterinary pharmaceuticals, nursing care rental fees, 3PL logistics contract fees, and future licensing revenue from the pharmaceutical business, thereby diversifying its revenue sources.
Company Strengths
Vital Net Inc. serves the Tohoku and Niigata regions, while KSK Co., Ltd. serves the 2 prefectures and 4 counties of the Kinki region, forming a two-pillar wholesale subsidiary structure with geographically complementary market coverage. In FY2026 (ending March 2026), pharmaceutical wholesale segment sales reached ¥572,860 million (approximately 94% of the group total), and the long-established customer base and delivery infrastructure in each market area make short-term imitation by competitors difficult.
The company focuses on sales of high-value-added products such as premium-priced new drug creation products, mainly anticancer agents, and influenza vaccines, achieving pharmaceutical wholesale segment sales of ¥572,860 million in FY2026 (ending March 2026), an increase of ¥8,246 million year on year. Distinctive pharmaceutical distribution services—including specialized MS activities conducted by MAPs and the Lab Access Department, as well as "Okusuri Aun" (a medication support service)—serve as the company's own unique differentiating factors.
At the end of FY2026 (ending March 2026), total net assets stood at ¥118,707 million, and total investments and other assets stood at ¥67,785 million. The company recorded a gain of ¥4,219 million on the sale of investment securities as extraordinary income, while implementing an annual dividend of ¥70 per share (dividend payout ratio of 46.0%) based on a basic policy of DOE of 3.0% or more. The company maintains an asset base that balances financial soundness with shareholder returns.
ENVALITH's Perspective
Performance Trend
Revenue maintained a stable growth trend, rising for five consecutive fiscal periods from ¥577,249 million in FY2022 to ¥610,497 million in FY2026 (CAGR of approximately 1.4%). Meanwhile, operating profit peaked at ¥5,556 million in FY2024 and ¥5,706 million in FY2025 before declining sharply to ¥4,027 million in FY2026. The main causes were the new recognition of ¥1,312 million in R&D expenses in the Pharmaceutical Manufacturing Business, together with an increase in SG&A expenses (+¥2,045 million year on year) driven by rising prices. As an external factor, downward price pressure from the April 2025 drug price revision also continued. Net income held roughly steady at ¥7,362 million, supported by special factors such as gains on sales of investment securities and gains from investment partnership operations, but underlying earning power is on a declining trajectory.
Growth Strategy
Transformation of the business portfolio through strengthening the profitability of the pharmaceutical wholesale business, entry into the pharmaceutical business, and expansion of nursing care rental M&A
MedLeapPharma Co., Ltd. was established in September 2025 as a new business handling the licensing, regulatory approval, and distribution of promising pharmaceuticals approved in the US/Europe but not yet approved in Japan. The new drug candidate 'Ferric Maltol (ST10)' has advanced to Phase II trials. The Medium-Term Management Plan 2027 period is allocated as an R&D phase, aiming for early approval.
Concentrated investment in the highly capital-efficient nursing care rental business to strengthen dominant market presence in the Keihanshin (Kyoto-Osaka-Kobe) area. In December 2025, Yachiyo Care Holdings Co., Ltd. was made a subsidiary (merged into Yachiyo Care Support Co., Ltd. effective March 31, 2026), expanding sales in the nursing care rental and other business to ¥5,048 million (up 10.3% year on year). However, losses continue.
Improving contribution profit by customer through continued item-by-item price negotiations based on distribution improvement guidelines, promotion of DX such as EOS-based order receipt and delivery digitalization, and operational efficiency gains through DX/AI utilization. Aiming to achieve the FY2028 (ending March 2028) target core operating profit margin of 1.15% or higher (FY2025 (ended March 2025) result: 0.95%).
Plans to reduce the ratio of cross-shareholdings to consolidated net assets to below 10% by FY2030 (ending March 2030) (FY2025 (ended March 2025) result: 37.5%; interim target of below 20% by FY2028, ending March 2028). Also implementing a share buyback program from May 15, 2026 to March 24, 2027, with an upper limit of ¥4.0 billion / 2 million shares. The dividend policy of a DOE of 3% or higher will also continue.
Last updated: July 19, 2026